Historic drug pricing reforms pass; Pfizer acquires GBT; The long search for non-opioid pain drugs; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
The Endpoints Weekly has officially crossed the 60,000 mark on subscribers — thanks to all of your support. As the editorial team grows, we’ve been able to do a lot more, with many of those on display this week. Be sure to check out Lei Lei Wu’s deep dive on pain R&D. If you missed it, you may also rewatch her companion panel here.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.